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Abstract
The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel
diseases (IBDs). The overall objective was to better understand and explore primary non responsentibodies; IFX, infliximab; ADA, adalimumab; CZP, Certolizumab pegol; PNR, primary non response to
to anti-TNF agent; ATI, antibodies to infliximab; ATA, antibodies to adalimumab; FcγR, Fc gamma
osorbent assays; RIA, radio-immunoassays; ANA, anti-nuclear antibodies.
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and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two
parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF
therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and
non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological
roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss
hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the
potential role of TNF independent inflammatory pathways.
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The introduction of drugs directed against tumour-necrosis
factor (anti-TNF) has greatly advanced the therapeutic arma-
mentarium for the treatment of inflammatory bowel diseases
(IBDs). Infliximab (IFX), followed by Adalimumab (ADA) and
Certolizumab pegol (CZP) have shown significant efficacy in
severe Crohn's disease (CD) refractory to conventional treat-
ments, including immunosuppressive drugs.1–3 Efficacy for
fistulizing CD has also been shown in a placebo controlled trial
with IFX and in a post-hoc analysis of a pivotal trial with ADA.2,4
This clinical efficacy has been associated with mucosal healing
and improvement in quality of life. The efficacy of anti-TNF
agents has also been shown to exert a major impact on the
outcome of important disease parameters (i.e. a reduction inhospitalizations and surgeries).5,6 However, some patients do
not respond to anti-TNF agents and a significant proportion of
responders may lose response over time.
The scientific committee of ECCO has launched the first
pathogenesis workshop which focused on this significant
clinical problem. The overall objective was to better
understand and explore primary non response (PNR) and
loss of response (LOR) to anti-TNF agents in IBD.
The outcome of this workshop is presented into two parts.
The first manuscript addresses definitions, frequency and
pharmacological aspects of anti-TNF therapy failure, includ-
ing pharmacokinetics of anti-TNF monoclonal antibodies
(mAbs) and immune and non-immune mediated clearance of
anti-TNF mAbs. The second manuscript focuses on the
biological roles of TNF and TNF antagonists, including
357Anti-TNF therapy failuresmechanisms of action of anti-TNF agents, TNF independent
inflammatory pathways, and paradoxical inflammation.2. Definition and frequency of failures with anti-
TNF monoclonal antibodies (Tables 1 and 2)
2.1. Primary non response in luminal Crohn's disease
In placebo controlled trials, the rate of no remission at week
4 was 80% with CZP, 67% with IFX and 64% with ADA.7–9 These
numbers were influenced by the induction regimen, mainly
for ADA. The rate of PNR at week 4 was 71% for CZP, 40% for
IFX and 41% for ADA.7–9 The influence of induction regimen
for ADA was not statistically significant.
In pivotal placebo controlled maintenance trials with open
label induction, the maximal response rate was observed at
week 12 for CZP and ADA and at week 10 for IFX. The rate of no
remission at these timepointswas 73%withCZP,3 58%with IFX1
and 50% with ADA (Abbott data on file).2 The rate of no
response was 64% and 54% with CZP when defined by a 100 and
a 70 points decrease in Crohn's disease activity index (CDAI),
respectively,3 29.2% with IFX (defined by a 70 points decrease
inCDAI)1 and 31% and 21%withADAwhendefined by100 and 70
points decrease, respectively (Abbott data on file).2 In these
trials, the response and remission rates were influenced by
disease duration. For example, no response was observed in
only 10% of patients having disease duration of less than 1 year
as compared to 43% of patients having disease duration greater
than 5 years, at week 26 with CZP.3
Mucosal healing has been evaluated with IFX therapy:
absence of mucosal healing was found in 71.1% at week 10
and 55.6% at week 54.10
In strategy trials, remission without steroids reached a very
high rate around 75% atweek 12with IFX. In these trials, IFXwas
combined for a few weeks with steroids, with or without
immunosuppressive treatment.6,11 Co-treatment with immuno-
suppressors was shown to decrease non response but only in
immunosuppressor-naïve patients 12. There was no clear effect
of immunosuppressor co-treatment in cases of immunosuppres-
sor failures.7–9
In single center uncontrolled series, absence of response
to induction were constantly lower than in controlled trials
and ranged from 40% to 10% only.13–16 In these series, lower
non response rates were associated with immunosuppres-
sives co-treatment, younger age, colonic disease, absence of
stricture, non smoking and elevated CRP.2.2. Primarynon response in fistulisingCrohn's disease
PNR to induction with IFX was 31% at 14 weeks.17 Absence or
incomplete closure at the same time point occurred in 52% of
patients.17 For ADA, data exist only for the 6 months time
point, with absent or incomplete closure in 70% of patients.2
Closure based only on clinical evaluation, does not equate
definitive healing as illustrated by magnetic resonance
imaging (MRI) assessment. After induction therapy with IFX
the vast majority of clinical responders (8/11) had persistent
inflammatory tracks on MRI.18 Single center reports and
uncontrolled series suggest that the combination of anti-TNFtreatment with an appropriate drainage of perianal lesions
and antibiotics may decrease non response rates.19,202.3. Primary non response in chronic active ulcerative
colitis
Only IFX has currently been adequately evaluated in
ulcerative colitis (UC). Absence of response to induction at
week 8 was around 35% and absence of remission around
65%.21 Absence of mucosal healing after induction was found
in 40% of patients.212.4. Secondary non response in luminal Crohn's
disease
Secondary non response or LOR to anti-TNF agents is defined
in those patients who initially respond to anti-TNF therapy
and subsequently lost clinical response. Most studies define
clinical response as a reduction in CDAI of ≥70 from baseline
and clinical remission as CDAIb150. Secondary non respon-
ders are therefore those patients not achieving these clinical
goals. For IFX, this is defined if occurring after the fourth
dose (0, 2, 6 and 14 weeks). For ADA, this is defined if
occurring after the induction phase which includes three
injections in decreasing doses of 160 mg, 80 mg and 40 mg
over a period of 4 weeks followed by 40 mg every other week
for a total of 6–12 week period (to achieve maximal
response). For CZP, loss of efficacy is present after the
induction phase which includes three 400 mg doses at 0, 2,
and 4 weeks.
Two placebo controlled trials evaluated IFX for the
maintenance of remission in CD. Clinical response was defined
as CDAI reduction≥70 frombaseline and clinical remission as a
CDAIb150. Rutgeerts et al. evaluated patients who initially
responded to IFX at week 44.22 Failure to maintain response
was observed in 38% of them. The proportion of patients not in
clinical remission by the end of follow up with IFX was 47%.
Hanauer et al. evaluated 335 IFX responders.1 The median
time to LORwas N54 weeks for IFX 5 mg/kg and 10 mg/kg. LOR
at week 54 was observed in 61% and 42% of patients on IFX
5 mg/kg and 10 mg/kg, respectively. The proportion of
patients not in clinical remission at weeks 30 and 54 were
61% and 71% respectively for IFX 5 mg/kg and 55% and 61.6%
respectively for IFX 10 mg/kg. Two trials evaluated the
secondary non response to Infliximab by assessing the need
to intensify the dose and/or frequency of IFX treatment.13,23
LOR was observed in 50%–54% of patients in these studies. A
recent large cohort of 614 patients receiving IFX was followed
up for a median of 55 months.13 The authors reported non
response rateof 21.6% by the end of followup. Finally, a recent
review of the literature by Gisbert and Panes evaluated data
from16 studies.24 The reported LOR rates ranged between 11%
and 48%. A total of 2236 patients were included in these
studies, providing 6284 patient years of follow up. The mean
percentage of patients with LOR to IFX calculated from these
studies was 37%. Since the follow up time varied between
these studies, it was suggested by the authors that the risk of
losing response to IFX is better expressed as incidence per
patient years of follow up. Using this calculation, the LOR to
IFX was 13.1% per patient year.
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nance of remission in CD. Similar to the IFX trials, clinical
response was defined as CDAI reduction ≥70 from baseline
and clinical remission as a CDAIb150. Colombel et al.
evaluated patients who initially responded to ADA at week
54.2 LOR was observed in 46% of the patients. The proportion
of patients not in clinical remission at weeks 26 and 54 were
60% and 64% respectively for ADA every other week and 53%
and 49% respectively for ADA every week. Sandborn et al.
evaluated ADA responders at week 56.25 The proportion of
patients not in clinical remission was 21% and 17% respec-
tively for ADA every other week and ADA weekly.
Two placebo controlled trials— PRECISE 1 and 2 evaluated
CZP for the maintenance of remission in CD.3,7 Clinical
response was defined as CDAI reduction ≥100 from baseline
and clinical remission as a CDAIb150. In the PRECISE 1 trial,
the rate of secondary non responders at week 26 was 38%.
The rate of clinical non remission at week 26 was 52%. In the
PRECISE 2, secondary non response at week 26 occurred in
38% of patients who initially responded to induction therapy.
Clinical non remission occurred in 52% of patients.
2.5. Secondary non response in fistulising Crohn's
disease
One placebo controlled trial evaluated IFX in the treatment
of patients with fistulizing CD.4 Response was defined as
reduction in the number of draining fistulas of at least 50%
from baseline and remission was defined as the absence of
draining fistulas. At week 54, 64% of the patients had loss of
response to IFX manifesting as actively draining fistulas.
2.6. Secondary non response in chronic active
ulcerative colitis
Two placebo controlled trials, ACTs 1 and 2, evaluated IFX
for the maintenance of remission in UC.21 Clinical response
was defined as a decrease in the Mayo score of at least 3
points from baseline and clinical remission as a total Mayo
score of 2 or less. In the ACT 1 trial, clinical non response at
weeks 30 and 54 were 49% and 55% respectively. Clinical non
remission at weeks 30 and 54 were 65% and 66% respectively.
Lack of mucosal healing was observed in 50% of patients at
week 30 and 55% of patients at week 54. In the ACT 2 trial,
clinical non response at week 30 was 53% for IFX 5 mg/kg and
40% for IFX 10 mg/kg. Clinical non remission at week 30 was
74.4% for IFX 5 mg/kg and 64.2% for IFX 10 mg/kg. Lack of
mucosal healing was observed in 54% and 43% of patients on
IFX 5 mg/kg and 10 mg/kg respectively.
2.7. Prevention of anti-TNF therapy failure
Published data from referral centers presenting the rates of
response to anti-TNF in routine practice have shown higher
response rates than in controlled trials reaching 60–90% of
response. These data suggest that an appropriate selection
of good candidates to anti-TNF therapy give better results,
but can also stem from different response definitions in
clinical trials versus everyday practice, or from a different
patient population with more severe disease enrolled in
clinical trials. In the SONIC study, patients with active lesionsat endoscopy had higher rates of response to IFX and
azathioprine.12
The use of immunosuppressors (azathioprine, 6-mercap-
topurine and methotrexate), in conjunction with IFX has
been shown to significantly reduce the proportion of patients
with antibodies to IFX (ATI), possibly leading to a more
favourable response and reduced need for dose escala-
tion.24,26,27 More recently, results from SONIC study,
demonstrated higher maintenance of remission rates at
6 months in the combination arm of IFX and azathioprine.
Immunosuppressors seem to protect against the induction of
antibodies to ADA (ATA) and antibodies to CZP as well.3,7 One
placebo controlled trial demonstrated that intravenous
hydrocortisone administered in a dose of 200 mg immedi-
ately prior to IFX infusion, significantly reduced formation of
ATI; 26% versus 42% in the placebo arm.28 It is not clear
however, whether this approach impacts long term effects
on LOR.
Results from several studies have demonstrated that
regularly scheduled IFX infusions are associated with a
decreased likelihood of ATI formation. Intermittent therapy
may predispose to formation of anti-drug antibodies and
increased LOR.29–31 On the other hand, Zabana and Cabre
found no difference in LOR between patients receiving
scheduled IFX maintenance therapy to those reintroduced to
IFX after a period of 4 months of no therapy in patients who
received the original 3 infusion induction regimen (15%
versus 10% respectively), suggesting that this issue needs
further evaluation.323. Pharmacokinetics of anti-TNF mAbs (Tables
3 and 4)
Serum half lives vary between the anti-TNF agents, when
administered in humans. Murine mAbs possess much shorter
half-life (2–3 days) compared to chimeric (8–10 days) and
humanized (20–23 days) mAbs. Etanercept has the shortest
half-life (4 days) while ADA and Golimumab exhibit a half-life
between 10 and 20 days. Elimination of therapeutic proteins
varies between individuals and is most likely influenced by
immunogenicity (anti-drug antibodies), concentration of
target antigens, FcγR polymorphisms as well as by differen-
tial clearance.
The pharmacokinetics of these agents is determined by
three basic factors: (1) the mode of administration (intra-
venous vs. subcutaneous), (2) drug half-life and (3) peak-to-
trough serum concentration. All these factors determine the
therapeutic window, introduced as a concept by Nestorov in
2005.33 The therapeutic window concept postulates that a
threshold trough serum concentration is required for
therapeutic efficacy. However, supra-therapeutic serum
concentration may increase the hazard of infections or
malignancy. The importance of a high peak concentration as
a consequence of intravenous administration for efficacy and
safety of anti-TNF agents in CD and UC has not been
established. Peak concentrations after IFX infusion are at
least 50 times higher than trough concentrations (100–
300 µg/mL vs. 1–10 µg/mL). This ratio is less prominent in
subcutaneously administered agents like ADA, CZP and
Etanercept. When administered at a dose of 40 mg every
359Anti-TNF therapy failuresother week in patients with rheumatoid arthritis and CD, the
trough serum concentrations of ADA range between 4 and
8 µg/mL.
The volume of distribution of IFX and ADA is comparable,
which means that these molecules spread similarly into body
compartments. It is unclear if this also implies that the
penetration in different tissues, such as inflamed gut
mucosa, is also similar. To our knowledge, distribution data
for CZP are not available.
3.1. Importance of pharmacokinetics for the
efficacy of anti-TNF therapy
When recommended doses are used, one can assume that
initially adequate trough serum concentration is obtained in
most patients and that low initial concentration is not the
reason for PNR. However, data testing this hypothesis are
scarce. In the original dose ranging induction trial with IFX, a
dose response association has not been reported.8 Similarly
in UC patients, IFX was not superior when given at a dose of
10 mg/kg compared to the 5 mg/kg.21 However, in the first
dose ranging trial with ADA in CD, a dose/response relation
was apparent.30 Nonetheless, in all these trials, the
relevance of early trough serum concentration for individual
responses was never reported.
Trough serum concentration of therapeutic antibodies is
probably more relevant for secondary LOR. The development
of anti-drug antibodies is intrinsically linked with the use of
therapeutic proteins.34 However, in clinical practice, only
antibodies which interfere with drug efficacy (neutralizing
antibodies) or instigate adverse events really matter.
Drug trough serum concentration is reliably assessed
regardless of anti-drug antibodies and also reflects the degree
of drug degradation. Therefore, this concentration may
represent a more clinically relevant surrogate marker for
LOR. IFX trough serum concentration correlate with the
presence of ATI and with duration of response, but this
correlation is not absolute.29,35 Also, a decrease in drug levels
may be driven bymechanisms other than the induction of anti-
drug antibodies. For patients with IBD, more relevant than the
underlying mechanism of decreased trough serum concentra-
tion is their chance of needing accelerated dosing due to
secondary LOR. This information may be inferred from clinical
trials. However, it is important to note that in the long term
trials with IFX, patients increased the dose in case of LOR
whereas with ADA, a shortening of dosing interval was used to
enhance drug exposure. In the first maintenance trial for
luminal CD with IFX, ACCENT 1, 30% of patients treated with
5 mg/kg iv stepped up to the higher dose group of 10 mg/kg
after 1 year because they experienced a disease flare.1 In the
maintenance trials with ADA, CHARM and CLASSIC II, the
percentage of patients that shortened their dosing interval to
40 mg weekly after 1 year was 27% and 46% respectively.2,25 In
the long term maintenance trial with IFX for fistulizing CD,
ACCENT 2, 25% of patients increased the dose to 10 mg/kg
because their fistulas started draining again.36
3.2. Treatment optimization in LOR
If despite optimizing the treatment strategy, the efficacy of
an anti-TNF agent fades in a patient with initial response,treatment flexibility is needed to counteract LOR. The two
main strategies available are: (1) increasing drug exposure by
shortening the dosing interval or increasing the dose and (2)
switching to another drug. To some extent, the therapeutic
intervention needs to be tailored to each individual patient.
To justify the first option of dose escalation, we need
evidence that low trough serum concentration is associated
with LOR and that increasing drug exposure restores
efficacy. In the ACCENT 1 trial, increasing the dose from 5
to 10 mg/kg and from 10 to 15 mg/kg restored response in
62% and in 69% of patients respectively.1 Conversely, in a
single center patient cohort in Leuven of 547 patients with
CD, 66% (75/108) regained clinical response by the end of
follow up after having shortened their dose interval
(Schnitzler 2009). Data in patients with IBD and with
rheumatoid arthritis suggest that IFX trough serum concen-
tration below 1 µg/mL correlate with LOR.35,37 In a retro-
spective cohort of CD patients at the University of Toronto,
ATI formation correlated with low trough concentration, CRP
and the absence of long term remission.35
In a prospective immunosuppressive withdrawal trial,
patients with CD and with low IFX trough serum concentra-
tion (below median) had higher CRP values and CDAI scores
than those with trough concentration above median.38
Hence, even if there is no absolute correlation between
trough serum concentration, ATI and the clinical response,
increasing drug exposure with an intention to restore trough
concentration to therapeutic values is a valuable strategy.
Data regarding the influence of trough serum concentration
on therapeutic efficacy has not been released from the
controlled trials that led to the market authorization of ADA
and CZP.2,3,7,9 However, in a retrospective cohort of CD
patients treated with ADA at the University hospital of
Leuven, trough serum concentration was linked to therapy
discontinuation. More interestingly, in patients who regained
clinical response after dose adjustment, the increment of
ADA trough serum concentration was higher than in those
who failed to restore response.39 Similar data were already
reported with the use of ADA in patients with rheumatoid
arthritis.40
The strategies of dose escalation have been very different
in clinical trials conducted with the different anti-TNF agents
IFX, ADA and CZP. Therefore, it is impossible to choose
between shortening dosing interval and increasing the dose
based on clinical trial experience. For ADA the European
label suggests dose intensification only by shortening the
interval between injections, but for IFX both options are
being employed in clinical practice. A post-hoc analysis of
the pharmacokinetic data collected in the ATTRACT main-
tenance trial with IFX in patients with rheumatoid arthritis,
suggests that shortening the interval will lead to higher
trough serum concentration than increasing the dose.37
In case of LOR despite optimization, other therapeutic
options, including switching to another anti-TNF is an option.
In the GAIN trial, specifically designed to include patients
with LOR or intolerant to IFX, remission rates 4 weeks after
an induction dose of 160/80 mg ADA were lower when
compared to those found earlier in the dose finding clinical
trial, CLASSIC 1, which included patients naïve to anti-TNF
therapy.9,41 This observation needs to be confirmed, but
recent clinical trial data with both ADA and CZP indicate that
prior exposure to IFX attenuates the response to a second
360 M. Allez et al.anti-TNF agent. The reason for discontinuing a first or a
second anti-TNF mAb (PNR, LOR and/or intolerance) does not
seem to influence the rate of response to a second or a third
anti-TNF.41–434. Immunogenicity of anti-TNF mAbs (Table 5)
4.1. Anti-TNF agents have different degree of
humanization
All anti-TNF agents are compounds produced by biotechnology
that mimic molecules found in the body, such as proteins and
oligonucleotides. Due to their molecular nature all these
agents need to be parenterally administered. Several strate-
gies have been followed in drug development to improve the
efficacy and tolerability of biological agents. Progress in
protein engineering has resulted in the replacement of
immunogenic non-human peptide sequences from human
ones, a technique called humanization.34,44 Third generation,
humanized antibodies (±95% human) (exhibiting only murine
Complementarity-Determining Regions, CDRs, and a few
mouse amino-acids in the VH and VL frameworks) and fourth
generation, fully (100%) human mAbs, are usually considered
less immunogenic as compared to chimeric (75% human, the
VH and VL being of murine origin) mAbs such as IFX. Anti-TNF
agents currently available differ in their degree of humaniza-
tion. Furthermore, their degree of immunogenicity is still
unclear, due in part to the fact that the methods of detection
of antibodies against anti-TNF antibodies vary among different
studies.4.2. Methods measuring ATI
Initial measurements for detecting ATI were mostly per-
formed using solid-phase enzyme-linked immunosorbent
assays (ELISA). This technique has a major disadvantage
because standard detection antibodies (e.g. labelled anti-
human Fc) used for the detection of anti-drug antibodies,
may also bind with the IFX human Fc moiety in these
particular assays. To overcome this problem, a sandwich
ELISA has been employed by several groups as well as by a
commercial manufacturer (Prometheus Laboratories, San-
Diego, CA, USA). In this technique, plated IFX serves as the
antigen, and is used again, in a biotinylated form, to detect
anti-drug antibodies bound to the plated IFX.29,45 However,
this alternative ELISA method has also several limitations. It
can detect only ATI that remain capable of binding to soluble
biotinylated IFX while being already bound to IFX-coated
plates (i.e. remaining divalent or polyvalent antibodies). In
addition, epitope masking in the plated IFX may lead to false-
negative results and the presence of soluble IFX in the serum
may compete with the plate-bound one for the binding of
ATI. In addition, spontaneously occurring anti-IgG antibodies
(rheumatoid factor) as well as other low-affinity antibodies
may bind non-specifically to the plate-coated IFX , yielding a
false positive assay result.46
The limitations of the sandwich ELISA have lead to the
development of alternative methods. A functional assay
assessing the capacity of patient sera to neutralize binding of
IFX to solid-phase TNF has been developed, but it doesnot allow the detection of non-neutralizing anti-TNF
antibodies.47
Fluid phase assays comprising radio-immunoassays (RIA)
have been also developed for ATI measurement. In general,
fluid phase RIA recognize ligands with highly conserved
conformations and are therefore less influenced by artefacts
due to formation of new epitopes or loss of epitopes occurring
after coating/coupling of proteins to solid-phase matrices.
This technique allows a useful correlation with clinical
response to IFX.46,48–50 A further advantage of fluid phase
RIA is that functional monovalent ATI are detected, such as
IgG4, which are not measured by sandwich ELISA, but
nevertheless constitute a significant amount of ATI in patients
with rheumatoid arthritis.46 On the other hand, fluid phase RIA
technology does not circumvent the interference stemming
from the presence of IFX in serum and is still limited for
detecting only lambda-chain containing ATI, which have been
shown to comprise 50% of the total IFX-ATI immune complexes
in serum.46 Other investigators used agarose-immobilized
protein A to capture serum immunoglobulins and then
measured radioactivity after addition of I125 labelled pepsin-
treated IFX.51 However, this method cannot overcome the
presence of IFX in serum, and may also underestimate ATI
other than IgG1 and IgG2, as the latter are preferentially
captured by protein A.
4.3. Methods measuring ATA
One method to measure ATA consists of adding radio-labelled
pepsin-digested ADA (i.e. the F(ab)'2 fragment of Adalimumab)
to Protein A-captured serum immunoglobulins, with subse-
quent measurement of Sepharose-bound radioactivity.40
Others have measured ATAs using sandwich ELISA technique,
whereby unlabelled ADA serves as the bound antigen, and
labelled ADA is employed in the detection phase.52 A fluid
phase RIA has also been developed.53 The readouts of this
technique were shown to correlate with clinical response to
ADA, or lack hereof, in patients with rheumatoid arthritis and,
most likely, with IBD. Since all these methods are similar to
those used for ATI as described above, they also share similar
technical limitations.
4.4. Immunogenicity and IFX
4.4.1. Allergic reactions
Acute infusion reactions need to be differentiated from
delayed reactions. Acute reactions are defined as reactions
occurring during or within 2 h of an infusion. They can be
severe or not. Severe reactions are usually defined as
reactions necessitating discontinuation of the infusion due
to significant dyspnoea or drop in blood pressure. Mild to
moderate acute reactions may include fever, slight decrease
in blood pressure, erythema, itching, rigor or shivering.
Delayed reactions occur 2 days to 2 weeks after reinfusion
of IFX. The symptoms can be quite severe and usually last 3–
5 days. Delayed reactions are usually attributed to serum
sickness like reactions. Possible symptoms include a cluster of
features (generalized stiffness, myalgias, arthralgias, fever,
and/or rash).
The main hypothesis behind these allergic reactions,
acute or delayed and severe or not, is that they are related to
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not been adequately studied and the only biological marker
available to assess immunization against the drug are the so-
called ATI.
4.4.2. Clinical relevance of immunogenicity and IFX
In all registration studies with IFX, ATI have been detected in
4 to 38% of patients (36,55). In the early post-marketing
clinical experience, up to 25% of patients developed
moderate or severe infusion reactions when IFX was used on
demand with and without concomitant immunosuppressive
therapy.
Since then, hallmark studies have shown a relationship
between ATI and infusion reactions. In a cohort of 125
consecutive patients with CD who were treated with episodic
IFX infusions in the University hospital in Leuven, a
correlation between IFX and ATI concentrations with clinical
efficacy, side effects (including infusion reactions), and the
use of concomitant medications before and 4, 8, and
12 weeks after each infusion was investigated.29 ATI were
detected in 61% of patients and in almost all of them these
were developed after the first or second infusion. The
cumulative incidence of infusion reactions was 27% and the
vast majority of these reactions occurred during the second
or third infusion. There was a strong correlation between the
concentration of ATI and the occurrence of infusion reactions.
The median concentration of ATI was 20.1 µg/mL (95% CI 3.0–
22.6) at the time of a first infusion reaction, as compared with
3.2 µg/mL (95% CI 1.6–4.9) among patients without an infusion
reaction (pb0.001). ATI concentration ≥8 µg/mL predicted a
higher risk of infusion reactions (RR 2.40; 95% CI 1.65–3.66;
pb0.001).
The median Infliximab concentration 4 weeks after an
infusion was significantly lower among patients with an
infusion reaction than among patients who never had a
reaction (1.2 µg/mL vs. 14.1 µg/mL, pb0.001). A significant
relation was also found between the serum IFX concentration
measured 4 weeks after an infusion and the concentration of
ATIs before that infusion (r=0.34, pb0.001). Once an
infusion reaction occurred, the median duration of response
to an infusion was shorter: 38.5 days (95% CI 34–51 days), as
compared with 65 days (95% CI 56–71 days; pb0.001).
Logistic regression analysis showed that the presence of ATI
was independently associated with a shorter duration of
response (pb0.001). Patients who were taking immunosup-
pressive agents had a lower incidence of ATI compared to
those who were not taking such agents (43% vs. 75%)
(pb0.01).29
In another cohort of 53 patients, an incidence of ATI of
36%, including all 7 patients with severe infusion reactions,
was found (28). The median ATI concentration in these
patients was 19.6 µg/mL. Eleven out of 15 patients (73%) who
lost response to IFX therapy were ATI positive compared to
none of 21 continuous responders. In addition to concurrent
use of immunosuppressive therapy, the administration of a
second infusion within 8 weeks from the first was protective
against ATI formation. In a subsequent study in the same
cohort, 80 patients were randomised to receive 200 mg of
hydrocortisone or placebo before each infusion. A lower
incidence of ATI was found among steroid pre-treated
subjects (26% vs. 42%). In another prospective study it was
demonstrated that patients receiving immunosuppressivetherapy had lower ATI formation compared to those receiving
IFX monotherapy (10% and 18%, respectively; p=0.02).54
Sequential measurement of ATI concentration through
the ACCENT 1 study has shown that ATI may develop at any
time during scheduled or episodic retreatment.54 However,
ATI formation is more pronounced in patients treated
episodically than in those treated in a scheduled manner,
being around 30% after 72 weeks in the episodic strategy as
compared to 10% and 7% in the maintenance strategy with
5 mg/kg and 10 mg/kg, respectively. Important information
provided by ACCENT 1 is that patients positive for ATI at any
time point may later become negative and that globally, the
proportion of patients positive for ATI at each time point is
not increasing over time, even with the episodic strategy.
However maintenance therapy has proven superior to
episodic treatment for various reasons. The most important
advantages of maintenance therapy over episodic treatment
include better response and remission rates, more thorough
mucosal healing, and better quality of life and reduced
number of disease-related surgeries and hospitalizations.
Recently the SONIC trial comparing IFX alone versus IFX plus
azathioprine versus azathioprine alone maintenance therapy
has shown remarkable and durable superiority for the
combination therapy of IFX with immunosuppressant over
an IFX maintenance regimen alone in immunosuppressive
naïve patients.12 The combination treatment yielded higher
IFX concentrations and a lower incidence of ATI compared to
infliximab maintenance monotherapy.124.5. Immunogenicity and ADA
4.5.1. Allergic reactions
ADA has been rarely reported to be related with systemic or
injection site allergic reactions. These reactions can be drug-
or host-specific and some of them seem to be IgE-mediated. In
clinical trials with ADA, approximately 1% of patients
experienced allergic reactions such as allergic cutaneous
eruptions, anaphylactic reaction, non-specified drug reaction
and urticaria. In addition, anaphylaxis and angioneurotic
edema have been reported rarely in post-marketing experi-
encewith ADA. Systemic allergic reactions clinically expressed
as asthma have been also reported.55
4.5.2. Clinical relevance of immunogenicity and ADA
ADA appears to be less immunogenic than IFX, in accordance to
its human nature.34,56 The formation of human anti-human
antibodies has been already reported long ago52,57 however, it
still remains unclear which part of ADA induces anti-human
antibody response.58
In the CLASSIC-I trial concomitant therapy with azathio-
prine and 6-mercaptopurine did not produce a significant
change in serum concentrations of ADA.9 The CHARM2 and the
CLASSIC-II25 studies have reported ATA formation in 2.8% of CD
patients irrespective of concomitant immunosuppressive
therapy. However, the CLASSIC II study was not powered nor
designed to demonstrate the protective role of azathioprine,
or methotrexate in the occurrence of ATA. In addition,
attempts to modulate the development of antibodies to anti-
TNF therapies through concomitant immunosuppression do not
necessarily prevent the need for dose escalation and/or dose
interval shortening. In the CLASSIC II trial, among the patients
Table 1 Primary non response.
Key messages
1. Almost a third of patients do not show response and 2/3
do not achieve remission.
2. However, when selecting only patients with active CD
(assessed by inflammatory markers and/or lesion
assessment), the absence of response is rare and ranges
between 10 and 30%, while it is around 40% in UC.
3. Maximal response rate is reached after 12 weeks.
4. A broad range of “response intensity” exists; full response
characterized by clinical remission and tissue healing only
occurs in a minority of patients (around 30%).
5. Response rate may be influenced by disease location,
duration and type, active inflammation, strictures, anti-
TNF dose, smoking and co-treatment.
Questions to be addressed in the future
1. What is the best definition of non response (criteria,
timing)?
2. What is the optimal induction regimen (dose, number and
frequency of dosage)?
3. What is the real benefit of co-treatments (for clinical
efficacy, healing)?
4. What are the response rates when treating stricturing CD?
Are there predictive factors of response?
5. What are the response rates in refractory proctitis?
Table 2 Secondary non response.
Key messages
1. Loss of response varies from around 50% per year in
placebo controlled trials to a slightly more than 10% per
year in smaller studies and monocentric experiences in
which treatment optimization (including dose escalation
and dose interval changes) is allowed.
2. Factors that may prevent loss of response include steroid
premedication, immunosuppressive co-treatments, and
maintenance treatment as opposed to episodic
treatment.
3. Treatment optimization with increased dose or shortened
interval allowed recovering response in 50–90% of the
patients.
4. The optimal method for dose optimization is yet to be
determined.
Questions to be addressed in the future
1. What is the best definition of loss of response?
2. What is the impact of induction regimen on long term
response and risk of loss of response?
3. What are the best optimization regimens (dose increase,
interval shortening, re-induction or co-treatment)?
4. Can the findings for infliximab be extended to the other
(humanized) anti-TNF agents?
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at weeks 24 and 56 respectively.25
In a recent study from the Leuven cohort of ADA patients,
who comprise at present the largest single center cohort
examining the relationship between ADA therapy, ADA
trough serum concentration and ATA formation, the great
majority of patients with undetectable trough serum
concentration also display ATA. These antibodies were
detected in 9.2% of the patients. Concomitant immunosup-
pressive therapy at baseline did not decrease the develop-
ment of ATA. Also, pre-existing ATI did not affect subsequent
response rate to ADA therapy or ATA formation.39 ATA were
also associated with non response to ADA in another study of
30 CD patients previously exposed to IFX.59 In this study, 57%
of patients receiving ADA after IFX discontinuation were ATIs
positive. ATA were detected in 5/30 (17%) patients and 4 out
of these five patients did not respond to ADA therapy. The
presence of ATA was associated with low trough serum ADA
concentration. According to this study, patients previously
treated with IFX exhibiting high levels of ATI demonstrate a
subsequent lower response rate to ADA than patients with
low levels of ATIs, a conclusion that is in contrast with the
data from the study from Karmiris et al.39
4.6. Limitations in measuring ATI and ATA
Notably, not only are the techniques for measurement of anti-
drug antibodies different but even the results obtained by the
different methods are not reported in a uniform or standard-
ized manner that would enable reproducibility across studies.
Thus, some studies report antibody levels in arbitrary units
according to serial dilutions of a reference serum, whereas
others report measurements in microgram/mL. Moreover,
there are hitherto no studies directly comparing the different
methods outlined above, and thus it is hard to draw firm
conclusions as to themost accurate and/or clinically beneficial
method of detection. Such comparative studies are needed in
order to ascertain the bestmethodology for anti-drug antibody
detection in terms of reproducibility, accuracy, and correla-
tion with loss of clinical response to anti-TNF agents. Also, the
real impact of ATI or ATA in the mechanisms of the early and
late allergic reactions and LOR to these drugs deserves further
studies before firm conclusions can be drawn. Furthermore,
the formation of these immune complexes (anti-TNF IgG1/
anti-IgG immune complexes) probably accelerates the clear-
ance ofmAbs through capture by cells expressing FcγRs. So far,
little is known regarding the fine mapping of antibody
specificity against anti-TNF mAbs.
5. Immune and non-immune clearance of
anti-TNF mAbs
Clearance of mAbs is a multi-factorial process, involving
different mechanisms that are either antibody-dependent or
host-dependent. The elimination of IgG is known to be
concentration dependent, where half-life decreases as a
function of increasing serum IgG concentrations. Catabolism
is the dominant elimination mechanism of mAbs. However,
the exact anatomical locations of this process have not been
identified.60,61 Specific binding sites on the Fc domain of the
mAb that interact with the FcRn and the Fcγ receptors seemto play a crucial role. The impact of the Fab domain on
clearance depends on the targeting antigen, namely if it is a
soluble or a membrane-bound one.
Table 3 Pharmacokinetics.
Key messages
1. Elimination of monoclonal antibodies varies between
individuals and is most likely influenced by
immunogenicity (anti-drug antibodies) and by differential
clearance.
2. The therapeutic window concept postulates that a
threshold trough concentration is required for
therapeutic efficacy.
3. The pharmacokinetics of monoclonal antibodies is
determined by three basic factors: the mode of
administration, drug half lives and peak-through
concentrations in serum.
4. The serum level of the monoclonal antibody is
significantly affected by antibody formation.
5. Loss of response to anti-TNF agents is only partly
explained by antibody formation and immunogenicity;
other factors including individual differences in drug
clearance are likely to play a role as well.
Questions to be addressed in the future
1. What is the correlation between concentrations of the
anti-TNF agent in the serum and in the inflamed tissue?
2. Are factors other than immunogenicity influencing levels
of anti-TNF in the blood?
3. Can the interplay between monoclonal antibodies and
antigens (i.e. antigen saturation and distribution) affect
IgG catabolism?
Table 5 Immune and non-immune clearance.
Key messages
1. Anti-drug antibodies can lead to loss of response by
increasing drug clearance.
2. Anti-drug antibodies are probably under-detected due to
technical shortcomings and imperfect test timing.
3. Monoclonal antibody humanization reduces antigenicity,
but is inferior to homology. Human antibodies may be also
immunogenic.
4. “Neutralizing” anti-idiotypic antibodies could lead to a
complete or partial inhibition of the anti-TNF mAbs
binding to TNF.
5. Scarce data exist on the role of PEG-linked molecules in
clearance of biologic agents consisting of Fab fragments.
6. Applying site-directed mutations within the Fc region
could influence the interplay between the monoclonal
antibody and FcRn or Fcγ receptors.
Questions to be addressed in the future
1. What causes formation of antibodies to anti-TNF
monoclonal antibodies in some patients but not in others?
2. How could we explain the differences between patients
with high and low concentrations of anti-drug antibodies?
3. What is the relative role of anti-drug antibodies on loss of
response?
4. What is the preferred technique to measure anti-drug
antibodies?
5. How to prevent anti-drug antibodies formation? What is
the risk/benefit ratio of concomitant treatments?
6. How should anti-drug antibodies presence direct our
management?
7. Can optimization of the pharmacokinetic properties of
monoclonal antibodies produce more efficient molecules
regarding catabolism?
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pathway
The neonatal Fc receptor (FcRn) is a major histocompatibil-
ity complex class-1-related receptor exerting a protective
role regarding IgG catabolism. This specific intestinal
transport receptor not only mediates neonatal IgG absorp-Table 4 In case of loss of response, drug trough levels and
antibody measurements could aid in decision making.
1. In patients with undetectable drug levels, antibody
measurement may be useful. Most will likely have high
anti-drug antibody titers and switching the drug is
probably the best option in this case.
2. In patients with low to intermediate drug readouts, and
absence of high titer antibodies, an attempt to restore
trough levels by dose escalation or shortening infusion/
injection intervals should be considered.
3. In patients with symptoms suggestive of active disease
despite high trough levels, disease reassessment
including the use of CRP, fecal calprotectin, and/or
imaging should be performed.
4. If these patients have active inflammation and no
infection, use of a compound with another mechanism of
action should be considered.tion, but also regulates IgG homeostasis.62 Mice genetically
lacking expression of FcRn demonstrated rapid IgG elimina-
tion with a rate increased up to 10–15 fold, while no change
was observed in the elimination of other immunoglobu-
lins.63,64 Fab fragments that lack the Fc domain making them
incapable for FcRn binding, demonstrate shorter half lives
than intact mAbs, although the presence of the PEGmolecule
also affects half-life. IgG binds FcRn via the Fc portion,
remaining in this complex steady state as long as intracel-
lular pH is mildly acidic and being released at physiologic
pH.65 Engineered mAbs should be delivered in very large
doses in order to significantly alter serum IgG concentration,
due to the large quantity of endogenous IgG that is present in
the body. On the other hand, they demonstrate altered
(usually increased) affinity to human FcRns and thus altered
(usually decreased) elimination rates especially through
mutation of IgG Fc residues.66,67 Human FcRn selectively
binds human IgG and this condition could explain the rapid
clearance of murine IgGs from human circulation.68 Human
IgG 1, 2 and 4 exhibit longer elimination half lives
(∼3 weeks) than IgG3 (1 week) due to a higher affinity to
FcRn.
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TNF mAbs
FcγRs belong to the immunoglobulin superfamily and induce
phagocytosis and destruction of opsonized microbes via
complement dependent or antibody-dependent cell-mediated
cytotoxicity. This family includes several different isoforms,
namely FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA
(CD16a) and FcγRIIIB (CD16b), which differ in their antibody
affinities due to their different molecular structure. FcγRI
demonstrates the highest degree of affinity with the IgG and
FcγRIIB the lowest.60,61 On the other hand, different IgG
isotypes such as IgG1, 2, 3 and 4, demonstrate unique recog-
nition and activation profiles, when interacting with various
FcγRs.69 The above mentioned characteristics regarding inter-
action between different FcγRs with different IgG isotypes
could also affect pharmacokinetics and clearance of the IgG
mAbs from the cells of the reticulo-endothelial system. For
example, homozygous FcγRIIIA-F/F158 polymorphism led to
more rapid elimination of opsonized red blood cells coatedwith
an anti-D IgG3 mAb by phagocytic cells in humans.70
Immune complexes containing mAbs can be eliminated
through interactions with FcγRs. Different couples of immune
complexes can be formed, made of TNFα and mAbs, or of
mAbs and anti-mAbs (ATI or ATA). The clearance efficacy is
likely related to the FcγRII and FcγRIII polymorphisms, hence
leading to various clinical consequences depending on the
patient.
5.3. Interaction of the mAbs with the target antigen
(TNFα): role of the variable region
Interaction with the target antigen can affect the elimination
rate of mAbs. This condition is dose-dependent. Low mAb
concentrations that do not saturate the antigen, demonstrate
shorter half-life and subsequently a higher clearance rate
compared to endogenous IgG; as the mAb's dose is increased
and the antigen is progressively saturated, an increase in half-
life and decrease in clearance rate is observed.
Monoclonal antibodies targeting soluble antigens usually
interact with the FcRn and undergo a non specific clearance
by the reticulo-endothelial system. Monoclonal antibodies
interacting with membrane-associated internalizing antigens
demonstrate a different elimination process characterized
by internalization of the antibody–antigen complex, fol-
lowed by degradation of the complex. In this case, the
contribution of the antigen to mAb's clearance depends on
antigen concentration and distribution as well as internali-
zation and turnover rate.60,61
5.4. Other factors associated with mAbs clearance
Apart from the above mentioned importance of the different
moieties of the mAb molecule in their clearance, other
factors have also been implicated in influencing this process.
These include: (1) Glycosylation process and susceptibility to
proteolysis: most of the mAbs are produced as recombinant
glycoproteins in eukaryotics cells and although IgG glycans
represent only 3% of the total IgG molecule mass, glycoforms
may impact the plasmatic clearance of the linked mAb; (2)
patient's characteristic like age, gender, body weight, bodysurface area and existence of a co-morbidity—i.e. diabetes;
and (3) concomitant treatment: a relationship between the
presence of methotrexate and a decrease in ADA clearance
has been implicated in rheumatoid arthritis patients.71
Methotrexate has been shown to be a potent inducer of the
expression of the FcγRI on monocytes in these patients.72
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